{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:16:43Z","timestamp":1789539403956,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinical-colorectal-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Colorectal Cancer"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.clcc.2018.03.005","type":"journal-article","created":{"date-parts":[[2018,3,8]],"date-time":"2018-03-08T01:20:26Z","timestamp":1520472026000},"page":"170-178.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies"],"prefix":"10.1016","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5962-1181","authenticated-orcid":false,"given":"Nele","family":"Boeckx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reija","family":"Koukakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5527-6838","authenticated-orcid":false,"given":"Ken","family":"Op de Beeck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5109-0267","authenticated-orcid":false,"given":"Christian","family":"Rolfo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Van Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Siena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Tabernero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Douillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5103-7095","authenticated-orcid":false,"given":"Thierry","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clcc.2018.03.005_bib1","doi-asserted-by":"crossref","first-page":"779","DOI":"10.7326\/0003-4819-113-10-779","article-title":"Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location","volume":"113","author":"Bufill","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clcc.2018.03.005_bib2","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejso.2014.11.001","article-title":"Is right-sided colon cancer different to left-sided colorectal cancer?\u2014A systematic review","volume":"41","author":"Lee","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib3","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejso.2010.12.004","article-title":"Colon carcinoma\u2014classification into right and left sided cancer or according to colonic subsite? Analysis of 29,568 patients","volume":"37","author":"Benedix","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ejca.2015.03.015","article-title":"Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17","volume":"51","author":"Brule","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clcc.2018.03.005_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1001\/jamaoncol.2016.3797","article-title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL and FIRE-3 trials","volume":"3","author":"Tejpar","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib6","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.clcc.2018.03.005_bib7","article-title":"Impact of primary tumor location on overall survival and progression-free survival in patients with metastatic colorectal cancer: analysis of CALGB\/SWOG 80405 (Alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib8","doi-asserted-by":"crossref","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","article-title":"Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer","volume":"28","author":"Peeters","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib9","doi-asserted-by":"crossref","first-page":"5469","DOI":"10.1158\/1078-0432.CCR-15-0526","article-title":"Analysis of KRAS\/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer","volume":"21","author":"Peeters","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2018.03.005_bib10","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","article-title":"Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer","volume":"25","author":"Van Cutsem","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib11","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1158\/1078-0432.CCR-12-1913","article-title":"Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer","volume":"19","author":"Peeters","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clcc.2018.03.005_bib12","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","article-title":"Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer","volume":"369","author":"Douillard","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clcc.2018.03.005_bib13","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00384-017-2800-1","article-title":"Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma","volume":"32","author":"Rivera","year":"2017","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.clcc.2018.03.005_bib14","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib15","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1093\/annonc\/mdx119","article-title":"Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies","volume":"28","author":"Boeckx","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib16","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1007\/s00432-014-1678-3","article-title":"Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12\/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial","volume":"140","author":"von Einem","year":"2014","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.clcc.2018.03.005_bib17","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/annonc\/mdr571","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306","volume":"23","author":"Stintzing","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Clinical Colorectal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002817304930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1533002817304930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T23:05:31Z","timestamp":1761519931000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1533002817304930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S1533002817304930"],"URL":"https:\/\/doi.org\/10.1016\/j.clcc.2018.03.005","relation":{},"ISSN":["1533-0028"],"issn-type":[{"value":"1533-0028","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies","name":"articletitle","label":"Article Title"},{"value":"Clinical Colorectal Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clcc.2018.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}